EJC Skin Cancer最新文献

{"title":"Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025","authors":"Marco Ardigò ,&nbsp;Markus V. Heppt ,&nbsp;Leyre Aguado ,&nbsp;Francesco Borgia ,&nbsp;Paolo Broganelli ,&nbsp;Isabel María Coronel Pérez ,&nbsp;Thomas Peter Dirschka ,&nbsp;Yolanda Gilaberte ,&nbsp;Giulio Gualdi ,&nbsp;Sarah Hobelsberger ,&nbsp;Pilar Luque Varela ,&nbsp;Blanca Moyano ,&nbsp;Girish K. Patel ,&nbsp;Susana Puig ,&nbsp;Paola Savoia ,&nbsp;Iris Zalaudek","doi":"10.1016/j.ejcskn.2026.100781","DOIUrl":"10.1016/j.ejcskn.2026.100781","url":null,"abstract":"<div><h3>Purpose</h3><div>This article provides an overview of the scientific content on tirbanibulin 1 % ointment, summarizing key Phase IV results and real-life experiences with tirbanibulin shared by dermatologists across Europe.</div></div><div><h3>Materials and Methods</h3><div>Summary of posters, oral presentation and symposium discussions related to tirbanibulin presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato Oncology (EADO) Congress held between 3rd and 5th of April 2025 in Athens, Greece.</div></div><div><h3>Results</h3><div>We report presented data on the efficacy/effectiveness, safety and tolerability of tirbanibulin 1 % ointment for the treatment of actinic keratosis (AK) on the face, scalp and décolleté. We also collected evidence supporting its use in AK in organ transplant recipients (OTR), solar damaged skin, pigmented AK (PAK), proliferative AK, hypertrophic AK, actinic cheilitis (AC), keratinocyte carcinoma (KC) and lentigo maligna (LM).</div></div><div><h3>Conclusions</h3><div>Overall, data from a Phase IV trial and real-world clinical practice suggest that tirbanibulin is an effective, safe and well-tolerated treatment for AK. Tirbanibulin may also be an option for OTR, patients with PAK, proliferative or hypertrophic AK, and even for conditions such as AC or KC, although the sample size is small in some of these groups and further evidence is needed.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100781"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicogenetic features of melanoma in children, adolescents and young adults (CAYA) associated with germline CDKN2A variants","authors":"R.M. Patricio da Silva-Junior ,&nbsp;F. Crespí-Payeras ,&nbsp;J. Mateu ,&nbsp;M. Potrony ,&nbsp;I. Cristiane Tosi ,&nbsp;B. Pereira Sorroche ,&nbsp;R. de Jesus Teixeira ,&nbsp;N. Vega ,&nbsp;P. Iglesias ,&nbsp;N. Castrejón de Anta ,&nbsp;C. Carrera ,&nbsp;S. Podlipnik ,&nbsp;J. Malvehy ,&nbsp;S. Puig","doi":"10.1016/j.ejcskn.2026.100810","DOIUrl":"10.1016/j.ejcskn.2026.100810","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100810"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Features and Outcomes of Vulvar and Vaginal Melanoma: A Tertiary Center Retrospective Cohort.","authors":"H. Leal ,&nbsp;S. Gil ,&nbsp;S. Vieira ,&nbsp;C. Morante ,&nbsp;S. Obando ,&nbsp;J. Mendieta","doi":"10.1016/j.ejcskn.2026.100811","DOIUrl":"10.1016/j.ejcskn.2026.100811","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100811"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desmoplastic Melanoma of the Skin: Clinicopathologic and Immunohistochemical Findings in Five Patients","authors":"D.V. Bulanov,&nbsp;D.R. Makhachev","doi":"10.1016/j.ejcskn.2026.100821","DOIUrl":"10.1016/j.ejcskn.2026.100821","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100821"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive acral haematoma presenting as longitudinal melanonychia with Hutchinson’s sign and nail dystrophy mimicking acral lentiginous melanoma","authors":"J.M. de Castro-Garrido ,&nbsp;A.X. Vence Nogueiras ,&nbsp;X. Cubiró Raventós ,&nbsp;L. Rusiñol Batlle ,&nbsp;C. López Sánchez ,&nbsp;O. Yélamos","doi":"10.1016/j.ejcskn.2026.100833","DOIUrl":"10.1016/j.ejcskn.2026.100833","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100833"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphovascular Invasion as an Independent Marker of Aggressive Biology in Cutaneous Melanoma","authors":"B. Taglione ,&nbsp;A. Maurichi ,&nbsp;G. Gallino ,&nbsp;D. Cortese ,&nbsp;I. Mattavelli ,&nbsp;R. Patuzzo ,&nbsp;C. Barbieri ,&nbsp;B.M. Scoppio ,&nbsp;E. Tolomio ,&nbsp;G. Spadola ,&nbsp;S. Mercurio ,&nbsp;M. Cossa ,&nbsp;B. Valeri ,&nbsp;M. Santinami","doi":"10.1016/j.ejcskn.2026.100857","DOIUrl":"10.1016/j.ejcskn.2026.100857","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100857"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of the timing of adjuvant immunotherapy initiation on recurrence-free survival in melanoma","authors":"P. Naranjo Alamo,&nbsp;E. Castro Gonzalez,&nbsp;A. Rebolledo Ruiz,&nbsp;M.L. Suarez Rizkallal,&nbsp;J. Sánchez Gutiérrez,&nbsp;I. Castaño Gonzalez","doi":"10.1016/j.ejcskn.2026.100847","DOIUrl":"10.1016/j.ejcskn.2026.100847","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100847"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid reduction of immune checkpoint inhibitor–associated pruritus with nemolizumab","authors":"Sophia Kreft,&nbsp;Franziska Grän,&nbsp;Sigrid Möckel,&nbsp;Berenice M. Lang,&nbsp;Bastian Schilling","doi":"10.1016/j.ejcskn.2026.101128","DOIUrl":"10.1016/j.ejcskn.2026.101128","url":null,"abstract":"<div><div>Pruritus is a prevalent and clinically significant adverse event of immune checkpoint inhibitors, often resulting in significant impairment of quality of life and potential interruption of oncologic therapy. Interleukin-31 (IL-31) is a key mediator of neuroimmune itch signalling and has been shown to be elevated in patients with pruritic cutaneous irAEs.</div><div>We report the case of an 80-year-old male patient with severe, chronic, therapy-refractory ICI-associated pruritus without primary inflammatory skin lesions, who demonstrated a rapid and complete response to IL-31 receptor blockade with nemolizumab. Pruritus resolved within 48 h after the first injection, with sustained remission and marked improvement in quality of life.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101128"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147537854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial","authors":"Carlo Resteghini ,&nbsp;Monica Variolo ,&nbsp;Sara Farinatti ,&nbsp;Andrea Alberti ,&nbsp;Valeria Tovazzi ,&nbsp;Paola Queirolo ,&nbsp;Maristella Saponara ,&nbsp;Giuseppe Agenziano ,&nbsp;Riccardo Marconcini ,&nbsp;Ketty Peris ,&nbsp;Paola Savoia ,&nbsp;Maria Chiara Tronconi ,&nbsp;Iris Zalaudek ,&nbsp;Paolo Antonio Ascierto ,&nbsp;Francesco Spagnolo ,&nbsp;Luigi Lorini ,&nbsp;Cristina Gurizzan ,&nbsp;Filippo Chersi ,&nbsp;Paolo Bossi","doi":"10.1016/j.ejcskn.2026.101146","DOIUrl":"10.1016/j.ejcskn.2026.101146","url":null,"abstract":"<div><h3>Background</h3><div>Sonidegib is active in locally advanced basal cell carcinoma (laBCC), but treatment-related adverse events (TRAEs) often limit continuation. In retrospective hedgehog inhibitor series, discontinuation after complete response (CR) has been associated with relapse. We evaluated whether a proactive tailored sonidegib schedule after CR could improve treatment continuation while maintaining disease control.</div></div><div><h3>Methods</h3><div>Adult patients with laBCC and sonidegib-induced CR entered TS1 (14 days on/14 days off); patients with persistent grade 2–3 toxicity, except alopecia, switched to TS2 (7 days on/21 days off). Treatment continued until progression or unacceptable toxicity. The primary endpoint was the proportion remaining on sonidegib at 12 months.</div></div><div><h3>Results</h3><div>Between January 2021 and December 2023, 22 patients were enrolled at ten Italian centers; data cut-off was November 2025. Three disease- and treatment-unrelated deaths occurred before month 12, leaving 19 evaluable patients. Twelve of 19 (63%) remained on treatment at 12 months. At cut-off, 14 of 19 (74%) had discontinued treatment, most commonly by personal/physician decision (6/19, 32%) or progression (5/19, 26%). Median discontinuation-free survival was 20 months (95% CI, 10-NE). Median RFS was 39 months (95% CI, 34-NE); 1- and 3-year RFS rates were 88% and 54%. The most common TRAE episodes were muscle cramps, alopecia, fatigue, and dysgeusia; 12 patients switched to TS2.</div></div><div><h3>Conclusion</h3><div>These single-arm phase II data support the feasibility of proactive pulsed sonidegib after CR and suggest that a tailored schedule may improve treatment continuation. Findings require cautious interpretation because comparisons with prior studies are indirect; follow-up and translational analyses continue.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101146"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148230591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Letter regarding “Cryotherapy for actinic keratoses: A cross-sectional survey of real-world clinical practice”","authors":"Husna Moola,&nbsp;Susanna Kannenberg,&nbsp;Willem Izak Visser","doi":"10.1016/j.ejcskn.2026.101163","DOIUrl":"10.1016/j.ejcskn.2026.101163","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101163"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148995298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}